Which structural features of tesamorelin acetate define the related-substance profile?
Tesamorelin is a synthetic 44-amino-acid, C-terminally amidated peptide matching the human growth hormone-releasing factor (1-44) backbone and carrying an N-terminal trans-3-hexenoyl group. Published evaluations describe it as a synthetic growth hormone-releasing factor analogue, including the laboratory code TH9507 (PMID:17086939; PMID:19243281; PMID:21283099). Research lots are commonly presented as the acetate salt after preparative reversed-phase purification and counter-ion exchange. Related substances group along three chemical axes. The backbone axis includes deletion and insertion sequences from solid-phase assembly, C-terminal truncations, and diastereomers from residual racemisation during coupling. Asparagine and glutamine support deamidation and aspartimide pathways. The growth hormone-releasing factor (1-44) framework contains methionine, so oxidised methionine species (+16 Da, and under stronger oxidative load +32 Da) are expected process or handling impurities. Many of these species differ from the parent by 1-16 Da and may sit on the tail of the main peak if the gradient is too steep. The N-terminal cap axis is specific to tesamorelin. Incomplete acylation yields des-hexenoyl peptide. Hexenoyl regioisomers and cis/trans isomerisation of the trans-3-hexenoyl alkene produce near-parent retention times and often identical intact mass. The unsaturated acyl handle is photo- and oxidation-sensitive; oxygenated acyl variants must be integrated separately from the parent. The salt and process-reagent axis includes residual trifluoroacetate from cleavage and preparative chromatography, and capping-derived acetylated truncations. Acetate itself is not a peptide-related ultraviolet peak, yet incomplete salt exchange changes peak shape, apparent recovery and net peptide content. A fit-for-purpose method therefore resolves des-hexenoyl material, oxidised methionine parent, deamidated and truncated sequences, diastereomers and hexenoyl isomers, and reports them as a table rather than a single purity percentage.
How is tesamorelin acetate related substances HPLC characterisation performed?
Tesamorelin acetate related substances HPLC characterisation is carried out by reversed-phase HPLC with ultraviolet detection at 214-220 nm, where the peptide-bond chromophore reports the parent and most sequence-related impurities. A wide-pore C18 phase (approximately 300 Angstrom) is appropriate for a 44-residue hexenoylated analyte; 100 Angstrom fully porous C18 materials often produce excessive retention, tailing and incomplete recovery of the more hydrophobic acylated species. Particle sizes in the 1.7-3.5 micrometre range support the peak capacity needed to split oxidised methionine and deamidated forms from the parent. The standard eluent system is ion-pair reversed-phase chromatography. Trifluoroacetic acid at 0.05-0.1% (v/v) in water and in acetonitrile sharpens peaks from this arginine- and lysine-rich sequence. Formic acid (typically 0.1%) is the mass-spectrometry-compatible alternative; it usually reduces retention and can fuse hexenoyl isomers that trifluoroacetic acid had separated, so the two methods are not interchangeable without a documented bridging comparison. Gradient slope across the parent window should be shallow (often 0.3-1.0% acetonitrile per minute). Column temperature between 30 and 50 degrees Celsius is a selectivity tool for diastereomers and must be recorded on the method sheet. Lyophilised tesamorelin acetate is dissolved immediately before the chromatographic run in a diluent close to the initial mobile phase, at a concentration that places the parent in the linear range and keeps minor peaks above the reporting threshold. Short solution hold times and protection from strong light reduce artifactual methionine oxidation and hexenoyl isomerisation. Carry-over is checked with blank runs after a concentrated parent run. Single-wavelength ultraviolet detection at 214 nm is used for area-percent related substances. Diode-array detection over 200-300 nm supports peak-purity ratiograms, which are informative because tesamorelin contains tyrosine and phenylalanine. Mass-spectrometric detection assigns identity; it replaces ultraviolet area-percent only when relative response factors have been established. System suitability should specify resolution of the parent from a critical pair (commonly oxidised methionine or des-hexenoyl tesamorelin), tailing factor, plate count, and repeatability of parent area and retention time.
How should chromatographic purity be distinguished from DAD peak purity?
Chromatographic purity, expressed as the area-percent of the main peak versus the sum of integrated peaks, is a different quantity from diode-array peak purity. Certificates for tesamorelin acetate research lots often print a single purity percentage without stating which definition was applied. Both results are required for a defensible characterisation. Chromatographic related-substances purity is obtained by integrating every peak above a stated reporting threshold, excluding the solvent front, blank-derived peaks and, where justified, non-peptide counter-ion features. Named related substances are listed individually; the remainder is reported as unspecified. Research laboratories commonly list individual unspecified impurities at or above 0.10% area and identify peaks at or above 0.5% area when orthogonal mass spectrometry is available. Those figures are laboratory choices, not a pharmacopoeial monograph for tesamorelin acetate, and they must be printed on the certificate. Diode-array peak purity is a spectral-homogeneity test of the parent peak only. A purity angle below the purity threshold, or a high match factor on ratiogram software, indicates that the ultraviolet spectrum is consistent across the peak. It does not quantify a co-eluting impurity that shares the same chromophore. For tesamorelin acetate the highest-risk co-eluents are hexenoyl cis/trans isomers and backbone diastereomers: they can satisfy a diode-array purity test and still inflate the parent area. A passing peak-purity index is therefore necessary but not sufficient. When reading a certificate, three elements should be present together: a chromatographic purity value with a related-substances table; a diode-array peak-purity outcome with wavelength range, noise and threshold settings; and a statement that the critical pair was resolved under the related-substances gradient. Integration parameters (peak threshold, minimum area, skim versus drop lines) change unspecified-impurity counts and must be locked in the method before the lot is analysed.
Which tesamorelin related substances require orthogonal LC-MS assignment?
Ultraviolet related-substances HPLC classifies peaks by retention time and area; it does not assign chemical structure. Several tesamorelin acetate impurity classes are isobaric or near-isobaric, so high-resolution LC-MS and tandem mass spectrometry are the orthogonal tools. Des-hexenoyl tesamorelin is the most straightforward process impurity: loss of the C6 acyl cap produces a defined monoisotopic mass shift and a more hydrophilic retention time. A high des-hexenoyl level points to incomplete N-terminal acylation or co-purification of unacylated chain and should be named on the impurity table. Oxidised methionine on the parent adds 16 Da (and 32 Da for the more oxidised form). Extracted-ion traces should align with ultraviolet peaks before the name is applied. Relative ultraviolet response of the S-oxide versus the parent at 214 nm is usually similar, so area-percent is commonly used without a unique response factor; that assumption belongs in the method text. Deamidation of asparagine or glutamine adds approximately 0.984 Da and often splits into isoaspartate/aspartate pairs. On a peptide of this mass, unit-resolution mass spectrometry may not distinguish deamidation from carbon-13 isotope contribution; accurate-mass data are preferred. Aspartimide intermediates appear as dehydrated species (minus 18 Da). Truncations and deletions are assigned from intact mass. Where the certificate claims sequence identity, tandem fragment ions should confirm the hexenoylated N-terminus and the amidated C-terminus. Literature descriptions of tesamorelin as a growth hormone-releasing factor analogue with an N-terminal hexenoyl modification (PMID:22298602; PMID:21668043) define the theoretical parent mass against which those deltas are calculated. Diastereomers and hexenoyl geometric isomers are frequently isobaric with the parent and cannot be named from intact mass alone; listing such a peak as unspecified impurity, same mass as parent, is more accurate than a forced structural name.
What system-suitability checks and CoA fields belong on Australian research lots?
A related-substances method that lacks documented system suitability is not a characterisation method. Before a tesamorelin acetate lot is integrated, the sequence should demonstrate a clean blank in the parent window, adequate sensitivity, precision, and resolution of a critical pair. Sensitivity is shown by a dilute parent preparation at the reporting threshold with signal-to-noise sufficient that an unspecified impurity at that level would be seen. Precision is shown by replicate chromatographic runs of the test solution, with parent area relative standard deviation inside internal limits (not more than 2.0% for five or six replicates is a common in-house rule; the certificate must quote the actual criterion). Resolution between the parent and the designated critical related substance should meet Rs of at least 1.5, or another laboratory-justified minimum. A briefly oxidised parent preparation that generates the methionine +16 Da species is a practical resolution probe when a qualified impurity marker is unavailable. Reporting thresholds must be pre-declared. Research certificates may set chromatographic purity at not less than 95.0% or 98.0% area and individual unspecified impurities at not more than 0.5% or 1.0% area. HPLC area-percent ignores non-chromophoric components: residual solvents, acetate counter-ion and water. Net peptide content, water by Karl Fischer titration, and acetate by ion chromatography or proton nuclear magnetic resonance are independent results. For Australian research procurement, the lot file should include batch and vial identifiers; sequence and acetate salt form; HPLC method identifier (column, gradient, wavelength, integration parameters, reporting threshold); labelled chromatogram and impurity table; diode-array peak-purity outcome; orthogonal intact-mass confirmation of the parent and of impurities above the identification threshold; and a research-use-only statement. The certificate lot number should match the vial label and the raw data-file names. Multi-vial orders from one synthesis lot share one related-substances chromatogram; different lot numbers require separate chromatograms. Local Australian stock, tracked dispatch and batch documentation are the relevant fulfilment attributes. Preparative fraction traces are not a substitute for an analytical related-substances run on the filled lot. Identity language should match the published description of tesamorelin as a synthetic growth hormone-releasing factor analogue (PMID:19243281; PMID:17086939) and include the hexenoyl modification. This paperwork supports method transfer and audit; it is not a therapeutic specification.
Order Tesamorelin with documentation
If this guide helped you evaluate Tesamorelin for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.
Open the Tesamorelin card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.
Frequently asked questions
What does related substances mean on a tesamorelin acetate HPLC certificate?
Related substances are process-related and degradation-related peptide impurities integrated on the related-substances chromatogram, reported as area-percent of named and unspecified peaks. They are not the acetate counter-ion, residual water or residual solvents. A complete certificate lists each named impurity, the unspecified total, the reporting threshold and the chromatographic purity of the parent.
Is diode-array peak purity enough to characterise tesamorelin acetate?
No. Diode-array peak purity tests spectral homogeneity of the parent peak. Hexenoyl geometric isomers and backbone diastereomers can share the parent ultraviolet spectrum and still sit under the main peak. Chromatographic purity with a resolved critical pair, a related-substances table and orthogonal mass confirmation of significant peaks are all required.
Why does the N-terminal hexenoyl group change the impurity profile?
The trans-3-hexenoyl cap creates des-hexenoyl, over-acylated, regioisomeric and cis/trans related substances that a non-acylated growth hormone-releasing factor (1-44) sequence would not show. Several of those species are isobaric with the parent, so retention selectivity and tandem confirmation of the acylated N-terminus matter as much as intact mass.
What should an Australian research CoA include for tesamorelin acetate?
Lot identifiers that match the vial; sequence and acetate salt form; HPLC method parameters and reporting threshold; labelled chromatogram; named and unspecified related substances as area-percent; diode-array peak-purity result; intact-mass confirmation; and a research-use-only statement. Multi-vial orders need one chromatogram per lot, not per carton.
Can LC-MS replace ultraviolet area-percent for tesamorelin related substances?
Only if relative response factors are established for each named impurity. Electrospray response varies with hydrophobicity, charge and co-eluting salt, so ion intensity is not automatically equal to ultraviolet area at 214 nm. The practical combination is ultraviolet related-substances HPLC plus mass assignment of peaks above the identification threshold.
How is acetate documented relative to peptide-related substances?
Acetate is the counter-ion, not a peptide-related substance on the ultraviolet chromatogram. It is measured by ion chromatography or proton nuclear magnetic resonance and is used in net peptide content calculations together with water. Residual trifluoroacetate from synthesis should be reported separately so that it is not mistaken for a related-substance peak.
References
- PMID:17086939 — Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor — Curr Opin Investig Drugs — 2006
- PMID:19243281 — Tesamorelin, a human growth hormone releasing factor analogue — Expert Opin Investig Drugs — 2009
- PMID:21283099 — Tesamorelin — Nat Rev Drug Discov — 2011
- PMID:22298602 — Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy — Ann Pharmacother — 2012
- PMID:21668043 — Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy — Drugs — 2011
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
